Effects of vasoactive agents on erythropoietin production.
D000704:Analysis of Variance; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001681:Biological Assay; D001794:Blood Pressure / Q000187:drug effects; D003250:Constriction; D003404:Creatinine / Q000494:pharmacology; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000096:biosynthesis*; D005260:Female; D006830:Hydralazine / Q000494:pharmacology; D007501:Iron / Q000378:metabolism; D007503:Iron Isotopes; D007668:Kidney / Q000098:blood supply; D008297:Male; D051379:Mice; D008954:Models, Biological; D009638:Norepinephrine / Q000494:pharmacology; D010100:Oxygen; D011086:Polycythemia / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D012077:Renal Artery / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology; D013268:Stimulation, Chemical; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D007503:Iron Isotopes; D014662:Vasoconstrictor Agents; D004921:Erythropoietin; D000804:Angiotensin II; D006830:Hydralazine; D012701:Serotonin; D003404:Creatinine; D007501:Iron; D010100:Oxygen; D009638:Norepinephrine